Generic Name and Formulations:
Gadobutrol 604.72mg/mL (1mmol/mL); soln for IV inj; preservative-free.
Indications for GADAVIST:
For use with MRI: in adults and children (including term neonates) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the CNS; or, to assess the presence and extent of malignant breast disease.
Adults and Children:
Give 0.1mL/kg (0.1mmol/kg) IV at a rate of 2mL/second, followed by a saline flush (to ensure complete injection).
Increased risk of nephrogenic systemic fibrosis among patients with renal impairment (eg, >60yrs, diabetes mellitus, chronic hypertension). Chronic, severe kidney disease (GFR <30mL/min/1.73m2). Acute kidney injury. Screen for renal impairment and other conditions. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. History of reaction to contrast media, asthma and/or allergic disorders. Have resuscitative equipment available. Monitor for signs/symptoms of hypersensitivity reactions. Avoid extravasation. Gadavist MRI may overestimate extent of malignancy in the diseased breast up to 50% of patients. Elderly. Pregnancy (Cat.C). Nursing mothers.
Do not mix with other drugs.
Paramagnetic contrast agent (Gadolinium-based).
Headache, nausea, dizziness; nephrogenic systemic fibrosis, hypersensitivity reactions.
Single-dose vials (2mL)—15; (7.5mL, 10mL, 15mL)—20; Single-use prefilled syringes (7.5mL, 10mL, 15mL)—5
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|